Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

UK pharma major GSK (LSE: GSK) has published results from its Phase III MATINEE trial evaluating Nucala (mepolizumab) in ...

GSK announced on Thursday that its monoclonal antibody ‘Nucala’, or mepolizumab, delivered a statistically significant and ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.